Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDNA NYSE:CORBF NASDAQ:FLGT NASDAQ:FTRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDNACareDx$13.66+4.2%$14.98$10.96▼$32.97$697.80M2.221.45 million shs2.03 million shsCORBFGlobal Cord Blood$1.05$1.02$0.25▼$1.75$127.63M-0.692,256 shsN/AFLGTFulgent Genetics$22.17+0.6%$19.81$14.57▼$23.56$678.60M0.83306,771 shs348,546 shsFTREFortrea$9.85+2.1%$6.36$3.97▼$25.28$876.22M1.811.99 million shs3.57 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDNACareDx+4.20%+5.32%+6.22%-19.36%-54.83%CORBFGlobal Cord Blood0.00%-32.26%+47.89%+5.00%-30.00%FLGTFulgent Genetics+0.64%+1.84%+26.76%+7.57%-2.98%FTREFortrea+2.07%+18.11%+58.87%+128.01%-56.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDNACareDx4.0891 of 5 stars3.32.00.04.22.00.81.9CORBFGlobal Cord BloodN/AN/AN/AN/AN/AN/AN/AN/AFLGTFulgent Genetics3.4812 of 5 stars2.31.00.04.12.63.30.6FTREFortrea2.9568 of 5 stars3.13.00.00.02.31.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDNACareDx 2.57Moderate Buy$27.67102.54% UpsideCORBFGlobal Cord Blood 0.00N/AN/AN/AFLGTFulgent Genetics 2.67Moderate Buy$25.3314.27% UpsideFTREFortrea 2.17Hold$12.2224.08% UpsideCurrent Analyst Ratings BreakdownLatest CORBF, FTRE, CDNA, and FLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025CDNACareDxWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform8/8/2025CDNACareDxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$19.00 ➝ $14.008/8/2025FTREFortreaEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetIn-Line ➝ In-Line$5.00 ➝ $7.008/7/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight ➝ Underweight$5.00 ➝ $6.008/5/2025FLGTFulgent GeneticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$20.00 ➝ $30.008/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$23.00 ➝ $21.008/4/2025FTREFortreaBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/4/2025FTREFortreaRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$7.00 ➝ $9.007/18/2025CDNACareDxCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $26.007/11/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$8.00 ➝ $7.007/9/2025FTREFortreaEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$6.00 ➝ $5.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDNACareDx$333.79M2.18$1.42 per share9.64$6.15 per share2.22CORBFGlobal Cord Blood$196.12M0.65$0.75 per share1.40N/A∞FLGTFulgent Genetics$303.22M2.24N/AN/A$36.32 per share0.61FTREFortrea$2.70B0.33$1.60 per share6.14$6.49 per share1.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDNACareDx$52.55M$1.0213.39N/AN/A17.97%18.03%12.88%11/3/2025 (Estimated)CORBFGlobal Cord Blood$79.04MN/A0.00∞N/AN/AN/AN/AN/AFLGTFulgent Genetics-$42.71M-$1.66N/AN/AN/A-16.83%-2.26%-2.10%11/14/2025 (Estimated)FTREFortrea-$328.50M-$11.38N/A7.70N/A-37.57%5.25%1.72%11/14/2025 (Estimated)Latest CORBF, FTRE, CDNA, and FLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CDNACareDx$0.12-$0.16-$0.28-$0.16$90.72 million$90.51 million8/6/2025Q2 2025FTREFortrea$0.06$0.19+$0.13-$4.14$631.61 million$710.30 million8/1/2025Q2 2025FLGTFulgent Genetics-$0.23$0.07+$0.30-$0.62$76.21 million$81.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDNACareDxN/AN/AN/AN/AN/ACORBFGlobal Cord BloodN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/AFTREFortreaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDNACareDxN/A3.303.00CORBFGlobal Cord BloodN/AN/AN/AFLGTFulgent GeneticsN/A6.016.01FTREFortrea1.871.021.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDNACareDxN/ACORBFGlobal Cord BloodN/AFLGTFulgent Genetics48.06%FTREFortreaN/AInsider OwnershipCompanyInsider OwnershipCDNACareDx4.40%CORBFGlobal Cord Blood0.50%FLGTFulgent Genetics31.76%FTREFortrea0.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDNACareDx74053.23 million50.89 millionOptionableCORBFGlobal Cord Blood1,200121.55 millionN/ANot OptionableFLGTFulgent Genetics1,31330.61 million20.89 millionOptionableFTREFortrea15,50090.80 million90.46 millionOptionableCORBF, FTRE, CDNA, and FLGT HeadlinesRecent News About These CompaniesRedwood Investment Management LLC Has $396,000 Stock Holdings in Fortrea Holdings Inc. $FTREAugust 30 at 5:44 AM | marketbeat.comInvesco Ltd. Grows Holdings in Fortrea Holdings Inc. $FTREAugust 30 at 3:30 AM | marketbeat.comFortrea Holdings Inc. (NASDAQ:FTRE) Given Average Rating of "Hold" by AnalystsAugust 29 at 4:07 AM | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Holdings in Fortrea Holdings Inc. $FTREAugust 29 at 3:14 AM | marketbeat.comCapital Fund Management S.A. Has $1.18 Million Stake in Fortrea Holdings Inc. $FTREAugust 28 at 4:51 AM | marketbeat.comFortrea (NASDAQ:FTRE) Shares Up 5.5% - Should You Buy?August 27 at 3:29 PM | marketbeat.com3 Reasons FTRE is Risky and 1 Stock to Buy InsteadAugust 27 at 6:41 AM | msn.comSpotting Winners: Azenta (NASDAQ:AZTA) And Drug Development Inputs & Services Stocks In Q2August 26, 2025 | msn.comVanguard Group Inc. Buys 69,005 Shares of Fortrea Holdings Inc. $FTREAugust 26, 2025 | marketbeat.comInvestors who lost money with Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation in connection with LawsuitAugust 25, 2025 | prnewswire.comAlgert Global LLC Raises Stock Holdings in Fortrea Holdings Inc. $FTREAugust 23, 2025 | marketbeat.comPublic Sector Pension Investment Board Acquires 61,006 Shares of Fortrea Holdings Inc. $FTREAugust 23, 2025 | marketbeat.comRepligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To KnowAugust 22, 2025 | msn.comReflecting On Drug Development Inputs & Services Stocks’ Q2 Earnings: Fortrea (NASDAQ:FTRE)August 22, 2025 | msn.comJill Mcconnell Sells 4,886 Shares of Fortrea (NASDAQ:FTRE) StockAugust 21, 2025 | insidertrades.comFortrea Holdings Inc. Earnings Call HighlightsAugust 21, 2025 | theglobeandmail.comJefferies Raises PT on Fortrea Holdings Inc. (FTRE); Truist Financial Maintains ‘Hold’ RatingAugust 19, 2025 | insidermonkey.comDeutsche Bank AG Has $8.80 Million Stock Position in Fortrea Holdings Inc. (NASDAQ:FTRE)August 17, 2025 | marketbeat.comFortrea (NASDAQ:FTRE) Stock Price Up 7.9% - What's Next?August 15, 2025 | marketbeat.com5 Insightful Analyst Questions From Fortrea’s Q2 Earnings CallAugust 14, 2025 | uk.finance.yahoo.comBrookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To KnowAugust 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCORBF, FTRE, CDNA, and FLGT Company DescriptionsCareDx NASDAQ:CDNA$13.66 +0.55 (+4.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$13.57 -0.09 (-0.66%) As of 08/29/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Global Cord Blood NYSE:CORBF$1.05 0.00 (0.00%) As of 08/29/2025Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.Fulgent Genetics NASDAQ:FLGT$22.17 +0.14 (+0.64%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$22.18 +0.01 (+0.05%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Fortrea NASDAQ:FTRE$9.85 +0.20 (+2.07%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$10.12 +0.28 (+2.79%) As of 08/29/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
